22.416 7.40%

Research Hotspot

Click Each Keyword to Figure Out More

Cohort Case Conventional Hepatic Cisplatin Level Life Middle Fluorouracil Acetate Selected Patient-reported Lack Axillary Older Organic Systemic Pediatric Incidence Proportion Approval Publication Observation Novel Conference Biliary Locoregional Failure Academic Accuracy Measurement Natural Postmenopausal D Bias Surveillance Anti-programmed Option Relative Microsatellite Alternate Antigen Watch Circulating Leucovorin Tolerability Biomarkers Pd-l1 First-line Support Expected Brain Food Supplementation Birth Oral Msh6 Needed Act Hodgkin Forward Neuroendocrine Ratio Hyperthermia Consideration Biopsy Cancer-beyond Hospice Inappropriate Call Genomic Incorrect Challenge Information Antibody Multigene Grain Tract Elderly Biology Imaging Parenthood Squamous Erbb2 Amount Highly Management Growth Doubt Egfr Sarcoma Instability Epidermal Cost Digital Is Text Open-label Without Cognitive Melanoma European Abstract Volatile Control All Framework Soft Burden-from Noninferiority Cardiovascular Misdiagnosis Accounting Breath Anti-pd-1 Fat Docetaxel Alisertib Absolute Gastrectomy Precision Panitumumab Contribution Prophylactic Doxorubicin Toward Veteran Evolving Intrahepatic Nephrectomy Documentation Wait Reporting Esophageal Cholangiocarcinoma Physician Hypofractionated Programming Therapy-related Measure Oncologic Allogeneic Agent Prediction Neglected High Landscape Peripheral Bleeding Programmed Al Adherence Nrg Comparing Pathophysiological Ductal Backward Better Resection Individual Doe Nodule Local Tremelimumab Low-risk Beyond Order Sunitinib Resonance Endocrine Oncologist Blood Modern Survivorship Detection Radiologic Family Axilla Diabetes China Portal Paradigm Mutational Erlotinib Sex Receptor-positive Informed Pathogenic Community Intervention Et Gleason Single-arm Phenomenon Career Height History Allele Opioid Open Technique Double Coverage Trials-in Fiber Neoplasm End Tomosynthesis Ra Panel Relapse Obesity Colon Society Overestimation Ascertained Molecular Innovation Article Area Skin Pd-1/pd-l1 Surgical Gammopathy Predispose Magnetic Discussion High-risk Intrinsic Variation Non-hodgkin Score Country Consequence Defect Virus Forest Conclusion Oligometastatic Genetic Javelin Carcinoma-missing Intravenous Assumption Attendance Benefit-to-harm Broad Gastroesophageal Lay Eruption Splice Worker Than Papillomavirus Enzalutamide Oncol Payment Participation Cost-effectiveness Monthly Inhibitors-from Statistical Activity Threshold Platinum-resistant Adolescent Following Network Prognosis Robust Glucocorticoid Load Undergoing Anthracycline Oncology/rtog Criterion Dietary End-of-life Cetuximab Hematopoietic Prevention Representation Deep Estimate Monoclonal Consolidation Disclose Race Susceptibility Retraction Combined Hsct Vein Grading Need Stem Avelumab Insight Plasma Follow-up High-dose Distal Meta-analyses Thyroid Neuropathy Type Hormone Pattern Goals-of-care Luminal Acid Next-generation Niraparib Gap Concurrent Radioisotope Reimbursement Refractory Who Geriatric Label Estrogen Scan Poor Vitamin Automated Influence Design Chek2 Thrombocytopenia-a Androgen-deprivation Reanalysis Prospective Significance Dose-escalation Cluster Ablative Tyrosine Anti-pd-1/pd-l1 Cancer-the Inhibition Clinically Racial Published Notice Ipilimumab Progression-free Ethical Classification Loss Braf

JAMA oncology - Impact Factor

The Impact Factor 2018 of JAMA oncology is 22.416, which is just updated in 2019. Compared with historical Impact Factor data, the Impact Factor 2018 of JAMA oncology grew by 7.40% . The Impact Factor Quartile of JAMA oncology is Q1. The Impact Factor (IF) or Journal Impact Factor (JIF) of an academic journal is a scientometric index that reflects the yearly average number of citations that recent articles published in a given journal received. It is frequently used as a proxy for the relative importance of a journal within its field; journals with higher impact factors are often deemed to be more important than those with lower ones. The Impact Factor measures the average number of citations received in a particular year (2018) by papers published in the journal during the two preceding years (2016-2017). Note that 2018 impact factors are reported in 2019; they cannot be calculated until all of the 2018 publications have been processed by the indexing agency. Besides, 59% scientific research articles published by JAMA oncology have received at least 1 citation in 2018. In addition to the 2-year Impact Factor, the 3-year Impact Factor and 5-year Impact Factor can provide further insights into the impact of JAMA oncology.

 Impact Factor 2018-19

JAMA oncology - Impact Factor Trend Prediction System

Impact Factor Trend Prediction System provides an open, transparent, and straightforward platform to help academic researchers Predict future journal impact and performance through the wisdom of crowds. Impact Factor Trend Prediction System displays the exact community-driven Data without secret algorithms, hidden factors, or systematic delay.

JAMA oncology Impact Factor Trend Forecasting System
 Real-Time Impact Factor Prediction & 2017 2018 2019 IF Impact Factor Trend - Academic Accelerator
JAMA oncology Impact Factor Trend. The chart clearly shows an uptrend of Impact Factor in 2018.
  • Impact Factor 2017 20.871
  • Impact Factor 2016 16.559
  • Impact Factor 2015 -


  • Article Volume 2017 151
  • Article Volume 2016 123
  • Article Volume 2015 102
  • ISSN
  • 23742445, 23742437
  • Open Access
  • Publisher
  • American Medical Association
  • Country/Region
  • United States
  • History
  • Categories
  • Medicine (miscellaneous) (Q1)

JAMA oncology - ISSN

The ISSN of JAMA oncology is 23742445, 23742437. An ISSN is an 8-digit code used to identify newspapers, journals, magazines and periodicals of all kinds and on all media–print and electronic.

JAMA oncology - ISSN

JAMA oncology - Subscription (non-OA) Journal

JAMA oncology is a Subscription-based (non-OA) Journal. Publishers own the rights to the articles in their journals. Anyone who wants to read the articles should pay by individual or institution to access the articles. Anyone who wants to use the articles in any way must obtain permission from the publishers.

JAMA oncology - Open Access

JAMA oncology - Publisher

JAMA oncology is published by American Medical Association, which is located in the United States. The Publication History of JAMA oncology covers 2015-ongoing.

JAMA oncology - Publisher

JAMA oncology - Categories

JAMA oncology is a peer-reviewed scientific journal. The scope of JAMA oncology covers Medicine (miscellaneous) (Q1).

JAMA oncology - Categories

JAMA oncology - Journal Metrics

It is impossible to get a true picture of impact using a single metric alone, so a basket of metrics is needed to support informed decisions. In addition to Abbreviation, Acceptance Rate, Review Speed, Research Hotspot and Template, several advanced Journal Metrics including Citescore, H-Index, Self-Citation Ratio, SJR (SCImago Journal Rank Indicator) and SNIP (Source Normalized Impact per Paper) can provide you comprehensive insights into the JAMA oncology.

JAMA oncology - Journal Metrics

Journal Ranking